Alberto Chiappori, MD
Enriched profileSenior Member, Oncology and Medicine, Thoracic Oncology Program · H. Lee Moffitt Cancer Center & Research Institute
Alberto Chiappori is Senior Member, Oncology and Medicine, Thoracic Oncology Program at H. Lee Moffitt Cancer Center & Research Institute. OpenAlex indexes 257 publications with 16,820 citations (h-index 48); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Alberto A. Chiappori, MD, is Senior Member, Oncology and Medicine, Thoracic Oncology Program at H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. The public record shows 257 publications with 16,820 citations (h-index 48), centered on Lung Cancer Research Studies, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 28 companies.
- Most recent indexed publication: 2022 · Clinical cancer research
- Top research focus: Lung Cancer Research Studies
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 28 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 105.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Industry payments
Updated 16 Oct 2026
28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Rigel Pharmaceuticals, Inc.Program year20256 payments
- JAZZ PHARMACEUTICALS INC.Program year20259 payments
- Partner Therapeutics, Inc.Program year202511 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
29.9%Kinase inhibitor29.9%Tagrisso100%Part D<11 patientsNervous system
28%Phenothiazine18.3%Prochlorperazine Maleate100%Part D≥37 patientsOpioid Agonist9.7%Oxycodone Hcl100%Part D≥14 patientsMetabolism & gastrointestinal
22.4%Serotonin-3 Receptor Antagonist22.4%Ondansetron Hcl100%Part D≥34 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
67 congress contributions (2004–2025) across AACR, ASCO, ASTRO per OpenAlex. The most recent:
- Abstract 6404: NOTCH1 drives immunogenicity through STING and improves survival with immune checkpoint blockade in small cell lung cancer
AACR Annual Meeting
AACR2025Co-author - Safety, tolerability, and preliminary efficacy results of a phase 1 study of LB2102, a dnTGFβRII armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC).
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/alberto-chiappori-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/alberto-chiappori-89128a31
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Alberto-Chiappori
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- X / Twitter
x.com/DAVAOnc/status/1938656443219038221
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mqa-internet.doh.state.fl.us ↗
- MD
Universidad Peruana Cayetano Heredia, Lima, Peru
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗ - Internship/Residency
Internal Medicine, Southern Illinois University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗ - Fellowship and Senior Fellowship
Medical Oncology-Hematology, Vanderbilt University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗
Editorial & leadership roles
journal and society appointments- Board Member
Florida Society of Clinical Oncology (FLASCO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lungevity.org ↗
Secondary affiliations
appointments beyond the home institution- Member
American Society of Clinical Oncology (ASCO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗ - Member
International Association for the Study of Lung Cancer (IASLC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Melissa Alsina, MD
H. Lee Moffitt Cancer Center & Research Institute
Richard Kim, MD
H. Lee Moffitt Cancer Center & Research Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center